Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix K-1. Documentation of GD administration and dose verification. Final report, June 1985-August 1988
Technical Report
·
OSTI ID:6957300
This study was conducted to evaluate the efficacy of the reversible acetylcholinesterase inhibitor, pyridostigmine bromide, as an addition to standard therapy with atropine and pralidoxime chloride (2-PAM), against the acute lethal effects of Soman, GD, using a primate model (male, Rhesus monkey). In addition, the pharmocokinetics of pyridostigmine bromide (intragastric), atropine (intramuscular), and 2-PAM (intramuscular) were individually examined in the primate model using three different dose levels for each compound. In the efficacy study, the combined prophylactic/post-challenge therapy regimen resulted in survival following an intramuscular challenge dose as high as 617 micrograms/kg in contrast to an estimated, unprotected, median lethal GD dose LD50 of 15.3 micrograms/kg for the same animals.
- Research Organization:
- Battelle Memorial Inst., Columbus, OH (United States)
- OSTI ID:
- 6957300
- Report Number(s):
- AD-B-127280/6/XAB; CNN: DAMD17-83-C-3129
- Country of Publication:
- United States
- Language:
- English
Similar Records
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix G-1. Atropine time of sampling, dose determination and calculations, syringe validation, and serum separation sheets. Final report, June 1985-August 1988
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development on task 85-18: Conduct of pralidoxime chloride, atropine in citrate buffer and pyridostigmine bromide pharmacokinetic studies, and comparative evaluation of the efficacy of pyridostigmine plus atropine. Final report, June 1985-August 1988
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix A. Protocol, amendments and deviations. Final report, June 1985-August 1988
Technical Report
·
Mon Aug 01 00:00:00 EDT 1988
·
OSTI ID:7227004
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development on task 85-18: Conduct of pralidoxime chloride, atropine in citrate buffer and pyridostigmine bromide pharmacokinetic studies, and comparative evaluation of the efficacy of pyridostigmine plus atropine. Final report, June 1985-August 1988
Technical Report
·
Mon Aug 01 00:00:00 EDT 1988
·
OSTI ID:6957270
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix A. Protocol, amendments and deviations. Final report, June 1985-August 1988
Technical Report
·
Mon Aug 01 00:00:00 EDT 1988
·
OSTI ID:7037102